Evaluate the efficacy of gradient compression sleeves in mitigating BCRL-related symptoms, improving limb function and enhancing quality of life in high-risk patients with breast cancer. Cancer
Conditions
Interventions
Eligible patients were randomly assigned in a 1:1 ratio to either the intervention group or the conventional care group. The randomization sequence was generated using a computer-based random number g
high-energy narrow-spectrum photon therapy was administered once daily for 20 min when indicated.
(3) Centripetal massage of the affected upper limb was performed under the supervision of healthcare p
alternatively, exercises including fist-clenching, elbow flexion,
Sponsors
National Natural Science Foundation of China
Eligibility
Sex/Gender
Female
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Women aged =18 years 2. Histopathological or cytological confirmation of breast cancer 3. Surgical procedures restricted to two types: 3.1. Modified radical mastectomy (i.e. total mastectomy plus ipsilateral axillary lymph node dissection [ALND], using either the Auchincloss or Madden technique) 3.2. Breast-conserving surgery (i.e. segmental mastectomy plus ipsilateral ALND or sentinel lymph node biopsy followed by ALND if indicated) 4. Supraclavicular lymph node dissection was performed at the surgeon’s discretion only if axillary lymph node metastases numbered =3 5. Classification as high-risk via the Post-Breast Cancer Lymphoedema Risk Assessment Scale (PBCL-RAS), with a threshold score of =13 points (consistent with the scale’s validated high-risk cutoff); key risk factors assessed included body mass index (BMI) = 25 kg/m², removal of =10 axillary lymph nodes, receipt of regional radiotherapy and taxane-based chemotherapy 6. Willingness to participate in the study
Exclusion criteria
Exclusion criteria: 1. History of psychiatric disorders 2. Impaired comprehension or reading ability 3. Severe dysfunction of major organs (e.g. heart, liver, kidneys) 4. Breast cancer being a metastasis from other malignant tumours rather than a primary cancer
Countries
China
Contacts
Public ContactLili Wang
Outcome results
None listed